Application of 18-Hydroxycortisol, 18-Oxocortisol, and 18-Hydroxycorticosterone Detection Reagents in the Differential Diagnosis of Hyperaldosteronism

Diagnostic Challenges of Primary Aldosteronism

Primary aldosteronism (PA) is a common cause of secondary hypertension, with subtypes including aldosterone-producing adenoma and idiopathic hyperaldosteronism, which require distinctly different treatment strategies. The traditional diagnostic workflow relies on aldosterone-to-renin ratio (ARR) screening and saline suppression testing, but ARR is subject to interference from medications, posture, serum potassium, and other factors, resulting in a high false-positive rate. In recent years, 18-hydroxycortisol, 18-oxocortisol, and 18-hydroxycorticosterone, as intermediate metabolites of the adrenal cortex, have been demonstrated to have a stronger correlation with aldosterone-producing adenoma. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) can simultaneously quantify these three steroids, providing more precise biochemical evidence for PA subtype differentiation.

Advantages of LC-MS/MS Technology in Multiplex Biomarker Detection

Compared with immunoassays, LC-MS/MS offers high specificity, high throughput, and simultaneous multi-component analysis. 18-Hydroxycortisol, 18-oxocortisol, and 18-hydroxycorticosterone have similar structures, and traditional immunoassays often exhibit cross-reactivity. Using LC-MS/MS technology with optimized chromatographic separation conditions and multiple reaction monitoring mode, target analytes can be effectively distinguished from interferents. Studies have shown that simultaneous detection of these three markers can more comprehensively reflect abnormalities in the aldosterone synthesis pathway. For example, 18-oxocortisol levels are significantly elevated in patients with aldosterone-producing adenoma, whereas the elevation is limited in patients with idiopathic hyperaldosteronism. This difference helps improve diagnostic specificity and reduce unnecessary invasive procedures such as adrenal venous sampling.

Key Points in Reagent Performance Verification and Clinical Evaluation

When using 18-hydroxycortisol, 18-oxocortisol, and 18-hydroxycorticosterone detection reagents, the following aspects should be considered:

Matrix matching of calibrators and quality control materials: Due to the low steroid content in serum (ng/mL level), stripped serum matrix should be used to ensure accuracy.

Method validation: Including linear range, precision, recovery, and stability. Generally, intra-assay and inter-assay coefficients of variation are required to be less than 15%, and recovery rates between 85% and 115%.

Establishment of reference intervals: Gender, age, posture, and circadian rhythm influences should be considered, and each laboratory is recommended to establish local reference ranges.

In clinical practice, this reagent combination can serve as a second-line confirmatory test for ARR-positive patients, aiding in the differentiation between unilateral and bilateral lesions. However, it should be noted that some patients may experience false positives due to the use of oral contraceptives or glucocorticoids, and relevant medications should be discontinued before testing.

Outlook and Compliance Reminders

With the increasing availability of mass spectrometry platforms, combined detection of 18-hydroxycortisol, 18-oxocortisol, and 18-hydroxycorticosterone is expected to become a new standard for PA subtype diagnosis. However, the clinical use of reagent kits must comply with the relevant regulations of the National Medical Products Administration for in vitro diagnostic reagent registration, and claims of "" or "replacing traditional methods" must not be made. Medical institutions should make comprehensive judgments in application by integrating imaging and adrenal venous sampling results.